Cassandra Shu,Harisha Atluri,Robert Kuehl,Pearl Shwe-Cho Tay,Ryan Mitchell Minikis,James Francis Hulvat,Alexander Jacob McVey,Ching Wah Chong
申请号：
US14821290
公开号：
US09545407B2
申请日:
2015.08.07
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Described herein is the Brutons tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
